Navigation Links
Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil
Date:5/20/2009

Breakthrough Isolaz Pro to Launch into High Growth Brazilian Market for Aesthetic and Medical Procedures

PLEASANTON, Calif., May 20 /PRNewswire/ -- Aesthera announced today the receipt of ANVISA clearance to market their proprietary Isolaz Pro photopneumatic(TM) based platforms in Brazil. ANVISA (Agencia Nacional de Vigilancia Sanitaria) is a Brazilian national health surveillance and regulatory agency charged with clearing all applications to market medical devices in Brazil.

Aesthera also announced its partner in the region, Sao Paulo based LBT Lasers, a leading distributor of advanced aesthetic technology solutions for physician practices. Aesthera's Isolaz Pro and other soon to be launched technologies will be exclusively represented by LBT sales professionals in the Brazilian market.

"This is the most recent milestone in our aggressive build-out of Aesthera's international distribution channel. We look forward to partnering with LBT Lasers as we introduce the Isolaz Pro(TM) to Brazilian physicians," said Alon Maor, president and CEO of Aesthera Corp. Aesthera's Isolaz platform is the only FDA cleared device for the treatment of comedonal and pustular acne, in addition to being cleared for the skin rejuvenation and hair removal. "LBT Lasers has a longstanding reputation as a premier provider of innovative aesthetic technology. Their strong network coupled with large customer base of over 300 physician offices will accelerate the rapid adoption of Photopneumatic platforms to over 5000 dermatologists in the Brazilian marketplace," he adds.

"The Isolaz Pro platform will offer Brazilian physicians a much needed treatment solution for acne as well as Profusion - a breakthrough skin therapy to enhance skin treatment outcomes for acne, body tightening, skin rejuvenation and skin lightening," says Alexandre Ferraz, CEO, LBT Laser. "We are proud that Aesthera has selected LBT Lasers as their exclusive distributor in our region. The addition of Aesthera's products to our offering demonstrates our commitment to bringing only the most innovative and effective technologies to our Brazilian customers. The Brazilian market for aesthetics is strongly positioned for continued robust growth in the coming years," he adds.

Aesthera's Isolaz platform will be launched to the Brazilian market at key academic meetings starting with the Teraderm - Sociedade Brasileira de Dermatologia meeting (May 22 - 23, 2009), the Congresso Brasileiro de Medicina Estetica (June 3 - 6, 2009) and the upcoming Congresso Brasileiro de Cirurgia Dermatologica between June 10 - 14, 2009.

About Photopneumatic(TM) Technology

Photopneumatic Therapy, that powers the Isolaz(TM) and Isolaz Pro(TM) system, is a proprietary combination of pneumatic energy and broad band light. Photopneumatic devices are the only laser or light based devices cleared for the treatment of inflammatory acne, comedonal acne and pustular acne. They are also cleared for the treatment of mild to moderate inflammatory acne. Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic Therapy is also cleared for the treatment of benign vascular and pigmented lesions and hair removal.

About Aesthera Corporation

Aesthera (www.AESTHERA.com) develops, manufactures and markets light-based aesthetic treatment systems - the Isolaz(TM) and Isolaz Pro(TM) platforms - based on proprietary Photopneumatic(TM) technology.

    Contact:
    Sarvar Kothavala
    Aesthera Corp.
    415.760.0902
    SKothavala@Aesthera.com


'/>"/>
SOURCE Aesthera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... 17, 2017 , ... Pono Ola , a mind-body wellness firm on ... the official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue balance ... for over a year, the patented Pono Board is the world’s only exercise balance ...
(Date:1/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX ... global Phase 2b induction study in ulcerative colitis ... integrin. The aim of this randomized, double-blind, placebo-controlled, ... and efficacy of PTG-100 in approximately 240 adult ... disease. "We are very pleased ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Tibbetts Award from the U.S. Small Business Administration. The Tibbetts Award ... economic or social impact […] and are considered the best of the best ...
(Date:1/13/2017)... Research and Markets has announced the addition ... Forecast to 2021" report to their offering. ... The biosimilars market is expected ... in 2016, at a CAGR of 26.3%. The ... type, and application. Factors such as rising incidence of various diseases, ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
(Date:12/15/2016)... ... announced the addition of the "Global Military Biometrics Market 2016-2020" ... military biometrics market to grow at a CAGR of 7.5% during the ... an in-depth market analysis with inputs from industry experts. The report covers ... report also includes a discussion of the key vendors operating in this ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at Trinity ... for graphene by combining the material with Silly ... sensitive pressure detector able to sense pulse, blood ... small spider.  The research team,s ... be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):